88
Participants
Start Date
September 30, 2010
Primary Completion Date
October 31, 2013
Study Completion Date
October 31, 2013
AAB-003 (PF-05236812)
0.5 mg/kg AAB-003, IV
AAB-003 (PF-05236812)
1 mg/kg AAB-003, IV
AAB-003 (PF-05236812)
2 mg/kg AAB-003, IV
AAB-003 (PF-05236812)
4 mg/kg AAB-003, IV
AAB-003 (PF-05236812)
8 mg/kg AAB-003, IV
Placebo
Placebo, IV
Albert Einstein Medical Center, Philadelphia
Foers Medical Arts Pharmacy, Bethesda
CBH Health, LLC, Rockville
Atlanta Center for Medical Research, Atlanta
MD Clinical, Hallandale
Franck's Pharmacy, Ocala
Munroe Regional Medical Center, Ocala
Renstar Medical Research, Ocala
Advanced Imaging of Ocala, Ocala
Brentwood Behavioral Healthcare, Flowood
Marty's Pharmacy, Flowood
Precise Research Centers, Flowood
Borgess Medical Center, Kalamazoo
Borgess Research Institute, Kalamazoo
KNI/Southwest Michigan Imaging Center, LLC, Kalamazoo
DePaul Health Center, St Louis
Millennium Psychiatric Associates, LLC, Creve Coeur
Early Phase Investigational Center, Escondido
Synergy Clinical Research Center of Escondido, Escondido
Memory Enhancement Center of America, Inc., Eatontown
Pharmacare USA, Edison
Central Jersey Radiology, Oakhurst
Belmont Center for Comprehensive Treatment, Philadelphia
Seoul National University Bundang Hospital, Department of Neurology, Seongnam-si
Inha University Hospital, Department of Neurology, Incheon
Samsung Medical Center, Department of Neurology, Seoul
Korea University Anam Hospital, Seoul
ASAN Medical Center, Seoul
Konkuk University Medical Center, Department of Neurology, Seoul
Lead Sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
INDUSTRY
Pfizer
INDUSTRY